Michael Davis

Davis Polk advised an ad hoc group of lenders under a $347 million first-lien and a $140 million second-lien term loan credit facility of CTI Foods, LLC …

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with the sale of substantially all of its assets to Currax Holdings LLC, an entity formed by affiliates of Highbridge…

Davis Polk is advising an ad hoc group of lenders (the “Ad Hoc Group”) under a $347 million first-lien and a $140 million second-lien term loan credit…

Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the United States Bankruptcy Code, entry into a “stalking horse” asset…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $150 million 10.5% senior notes due 2020 (to be consolidated and…

Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction, which is subject to customary closing conditions and the approval of…

Davis Polk is advising Baker Hughes, a GE company on a series of long-term agreements that amend the commercial and technological relationships with General Electric Company. Under the…

Davis Polk is advising ORIX Corporation USA on its acquisition of NXT Capital Inc. The transaction, which is expected to close in August 2018, is subject to customary closing conditions and…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…

Davis Polk is advising Metalmark Capital in connection with the sale of WorldStrides. Under the terms of the sale and merger agreement, Metalmark and its co-investors have agreed to sell…